# Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions

> **NCT05439408** · PHASE1 · COMPLETED · sponsor: **Xspray Pharma AB** · enrollment: 110 (actual)

## Conditions studied

- Biological Availability

## Interventions

- **DRUG:** Dasatinib ASD 100 mg
- **DRUG:** Dasatinib 140 MG [Sprycel]

## Key facts

- **NCT ID:** NCT05439408
- **Lead sponsor:** Xspray Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-07
- **Primary completion:** 2021-06-25
- **Final completion:** 2021-06-25
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05439408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05439408, "Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05439408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*